Heidelberg-based MedTech company Precisis GmbH, which specialises in neuromodulation therapies, has appointed Karl Stoklosa as its new CEO, effective September 1, 2024. Previously, Stoklosa held various leadership positions at Abbott Laboratories, most recently serving as Director of Global Marketing for the CRM Division. He succeeds Angela Liedler, who has successfully led the company since its early years.
Founded in 2014, Precisis has established itself as an innovator with the EASEE庐 brain pacemaker, a minimally invasive solution for the treatment of epilepsy. The company combines cutting-edge technology with a deep understanding of the needs of patients and healthcare professionals.
听
听
With a clear focus on core markets in the UK, Europe and the USA, Precisis aims to improve the quality of life for people worldwide. Stoklosa鈥檚 appointment marks the beginning of a new phase for the Heidelberg-based company, which has already established itself with the EASEE庐 brain pacemaker.
Dr. Felix Baader, Chairman of the Advisory Board at听Precisis听said, 鈥淲ith Karl Stoklosa at the helm, we are setting a clear course for the future of听Precisis. He brings not only extensive international experience but also the vision and determination needed to take our company to the next level.鈥�
听
More from News
- From Driverless Cars To Parentless Parenting: Is Sam Altman Running Out Of Things To Outsource?
- How Does Google Intend On Producing 15 Million AI Chips Over The Next Two Years?
- TikTok Parent ByteDance Has Officially Passed The $4 Billion Mark In AI Revenue
- Russia鈥檚 Latest Move Against Pavel Durov Shows That Telegram Is No Longer Just A Messaging App
- Experts React To The UK鈥檚 Decision To Make Tech Subjects Compulsory In Schools
- Microsoft Has Confirmed Copilot鈥檚 Super App Will Launch Soon 鈥� But What Is It For?
- G2A.COM鈥檚 Autonomous AI Agent Dave Helps Sellers Resolve 14,400 Support Tickets In 63 Days
- Why One MedTech Company Chose a Computer Graphics Conference To Launch Its Next AI Platform
听
鈥淭he MedTech industry is evolving rapidly, and we are confident that Stoklosa will drive听Precisis鈥檚 momentum forward and inspire our team.鈥�
鈥淭his leadership change marks the end of an era characterized by the outstanding work of Angela Liedler. Under her leadership, the innovative EASEE庐 brain pacemaker was successfully brought to market鈥攁 milestone in epilepsy treatment. Her entrepreneurial foresight and dedication remain an inspiration to all of us,鈥� Baader added.
Ben Fear, Precisis Area Manager in the UK said; 鈥淚t鈥檚 hugely positive news听to have someone of Karl鈥檚 experience join Precisis. His previous global roles within major Neuromodulation companies will undoubtedly prove to be an asset to Precisis as we continue our quest to improve the lives of patients suffering from functional brain disorders, with our truly innovative EASEE system.鈥�
Karl Stoklosa speaking about his new role said, 鈥淚t is a privilege to take on the leadership of Precisis at such an exciting time. Our goal is to improve the quality of life for millions of epilepsy patients worldwide through groundbreaking technologies.
鈥淚 am determined to further enhance Precisis鈥檚 innovative strength and set new benchmarks in neuromodulation.鈥�
Stoklosa is a renowned global executive known for consistently steering towards success. His career has been marked by successful strategies and innovations, most recently as Director of Global Marketing at Abbott Laboratories, where he made significant contributions to the CRM Division. He holds an MBA from the prestigious University of Chicago Booth School of Business.
